Alnylam Completes Enrollment in ILLUMINATE-C Phase 3 Study of Lumasiran, an RNAi Therapeutic, for the Treatment of Advanced Primary Hyperoxaluria Type 1Business Wire • 12/03/20
Alnylam Announces Innovative Value-Based Agreement Framework for OXLUMO™ (lumasiran) to Accelerate Access for Patients with Primary Hyperoxaluria Type 1 and Deliver Ultra-Rare Orphan Disease Pricing Solutions to U.S. PayersBusiness Wire • 11/24/20
Alnylam Announces U.S. Food and Drug Administration (FDA) Approval of OXLUMO™ (lumasiran), the First and Only Treatment Approved for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Pediatric and Adult PatientsBusiness Wire • 11/24/20
Alnylam Receives Approval for OXLUMO™ (lumasiran) in the European Union for the Treatment of Primary Hyperoxaluria Type 1 in All Age GroupsBusiness Wire • 11/19/20
Alnylam Seeing A Rebound In Onpattro And Encouraging Early-Stage Hypertension DataSeeking Alpha • 11/17/20
Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of HypertensionBusiness Wire • 11/13/20
Alnylam Pharmaceuticals, Inc (ALNY) CEO John Maraganore on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/05/20
Alnylam Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Period ActivityBusiness Wire • 11/05/20
Alnylam Wins Prestigious Prix Galien Award for Best Biotechnology Product with First-Ever Approved RNAi Therapeutic, ONPATTRO® (patisiran)Business Wire • 10/30/20
Alnylam to Webcast Conference Call Discussing Third Quarter 2020 Financial ResultsBusiness Wire • 10/22/20
Alnylam Presents Positive Results from ILLUMINATE-B Phase 3 Study in Pediatric Patients with Primary Hyperoxaluria Type 1 at the American Society of Nephrology Kidney WeekBusiness Wire • 10/22/20